CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

CRISPR Therapeutics,Inc. and ViaCyte, Inc., announced that Health Canada has approved the companies’ Clinical Trial Application for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes. Initiation of patient enrollment is expected by year-end.